Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01460498 · ClinicalTrials.gov registry record · Phase 1
Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01460498: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01460498 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01460498, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a 2 part study. The goal of the first part of this clinical research study is to find the highest tolerable dose of azacitidine that can be given with a TKI that you are already taking (such as Gleevec, Sprycel, or Tasigna). The safety of this drug will also be studied. The goal of the second part is to see if this combination may improve your response to the TKI you are already taking. Azacitidine is designed to change genes that are thought to cause leukemia. By changing these genes, the drug may help to stop them from causing the disease to grow.
Interventions
- DRUG Azacitidine
- DRUG Azacitidine (AZA)
- DRUG Tyrosine kinase inhibitor (TKI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2012-08-08 |
| Est. Completion | 2019-08-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01460498
The ClinicalTrials.gov registry entry for NCT01460498 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Azacitidine is the first listed.
NCT01460498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01460498 about?
NCT01460498 is a clinical study titled "Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)". This is a 2 part study. The goal of the first part of this clinical research study is to find the highest tolerable dose of azacitidine that can be given with a TKI that you are already taking (such as Gleevec, Sprycel, or Tasigna). The safety of this drug will also be studied. The goal of the secon...
What is the current status of trial NCT01460498?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2012-08-08. Estimated completion is 2019-08-07.
What interventions are being tested in trial NCT01460498?
The interventions under investigation include: Azacitidine (DRUG), Azacitidine (AZA) (DRUG), Tyrosine kinase inhibitor (TKI) (DRUG).
Who is sponsoring clinical trial NCT01460498?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.